Case Study: Signant Smartsignals® RTSM & Clinical Drug Dispensation

A pharmaceutical company implemented Signant Health's RTSM solution in a Phase 2 multiregional trial for schizophrenia patients to effectively manage investigational product dispensing and maintain study balance across three subgroups over 26 weeks. The trial, involving 150 adult participants across 35 sites, aimed to ensure sufficient drug doses for variable visit schedules while minimizing waste and addressing expiry challenges.

The study also needed to maintain balance across subgroups stratified by anti-psychotic medications, prevent duplicate subject allocation impacting efficacy data reliability, and manage the return and destruction of unused investigational products. These challenges were crucial for the successful execution and integrity of the trial.

Find out what happened next by downloading the case study below.